Retrosynthetic software finds experimentally validated supply routes for umifenovir
Retrosynthesis software proposed alternative chemical supply routes for the antiviral umifenovir and eleven other antiviral and anti-inflammatory drugs. The authors experimentally validated four routes to umifenovir and one route to bromhexine, one of which converts six C-H bonds. The work is a proof of route feasibility for supply-chain resilience, not a new therapeutic claim.
Technology: Computer-aided retrosynthesis software with exclusion of known starting materials
Publication: Peer-reviewed paper · Test context: direct test. Catalog categories, not an evidence grade.
Result, AI contribution and limits
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
- Publication status: Peer-reviewed paper
- Test type: direct test
- Tested: The authors experimentally validated four routes to umifenovir and one route to bromhexine proposed by the software.
- Still unknown: Not reported.
- AI role: Retrosynthesis software proposed alternative supply routes for umifenovir and other antiviral and anti-inflammatory drugs.
Evidence sources: https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=DOI:10.1038/s41467-021-27547-3&resultType=core&format=json
The legacy label “Not reported” does not distinguish information absent from reviewed material from information not assessed. It is not a scientific finding of absence.
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review scope and date are not recorded; source checked does not establish full-text review.
Citations: at percentile 87 of works of the same type, year and subfield (OpenAlex work metrics, 38 citations; as of 15 Nov 2026). Attention, not a measure of correctness; not part of the score.
Editorial assessment: Impact 3/5 · Validation 3/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Follow-up and relationships
No follow-up recorded; this is not a claim that no follow-up exists.
Follow-up review scope and date are not recorded.
No source-supported relationships recorded.